- Home
- VIAV vs IBRX Comparison
VIAV vs IBRX Comparison
Compare VIAV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIAV
- IBRX
- Stock Information
- Founded
- VIAV 1923
- IBRX 2014
- Country
- VIAV United States
- IBRX United States
- Employees
- VIAV N/A
- IBRX N/A
- Industry
- VIAV Semiconductors
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VIAV Technology
- IBRX Health Care
- Exchange
- VIAV Nasdaq
- IBRX Nasdaq
- Market Cap
- VIAV 2.0B
- IBRX 2.4B
- IPO Year
- VIAV 1993
- IBRX N/A
- Fundamental
- Price
- VIAV $9.17
- IBRX $2.09
- Analyst Decision
- VIAV Buy
- IBRX Strong Buy
- Analyst Count
- VIAV 8
- IBRX 5
- Target Price
- VIAV $12.69
- IBRX $11.35
- AVG Volume (30 Days)
- VIAV 2.5M
- IBRX 8.8M
- Earning Date
- VIAV 05-01-2025
- IBRX 05-16-2025
- Dividend Yield
- VIAV N/A
- IBRX N/A
- EPS Growth
- VIAV N/A
- IBRX N/A
- EPS
- VIAV 0.02
- IBRX N/A
- Revenue
- VIAV $1,045,800,000.00
- IBRX $14,745,000.00
- Revenue This Year
- VIAV $10.56
- IBRX $579.28
- Revenue Next Year
- VIAV $7.78
- IBRX $179.96
- P/E Ratio
- VIAV $406.20
- IBRX N/A
- Revenue Growth
- VIAV 3.34
- IBRX 2270.58
- 52 Week Low
- VIAV $6.60
- IBRX $1.83
- 52 Week High
- VIAV $12.91
- IBRX $9.16
- Technical
- Relative Strength Index (RSI)
- VIAV 34.42
- IBRX 37.22
- Support Level
- VIAV $8.75
- IBRX $1.83
- Resistance Level
- VIAV $10.94
- IBRX $2.63
- Average True Range (ATR)
- VIAV 0.38
- IBRX 0.19
- MACD
- VIAV -0.10
- IBRX -0.05
- Stochastic Oscillator
- VIAV 37.68
- IBRX 25.00
About VIAV Viavi Solutions Inc.
Viavi Solutions Inc. is a global provider of network test, monitoring and assurance solutions to communications service providers, enterprises, network equipment manufacturers, civil government, military and avionics customers. The company also offers high-performance thin-film optical coatings, providing light management solutions to anti-counterfeiting, 3D sensing, electronics, automotive, defense and instrumentation markets. Its operating segments include Network Enablement, Service Enablement, and Optical Security and Performance Products. Geographically, it derives a majority of revenue from the United States.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.